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Background: Intratumor heterogeneity may be responsible of the unpredictable aggressive clinical behavior that
some clear cell renal cell carcinomas display. This clinical uncertainty may be caused by insufficient sampling,
leaving out of histological analysis foci of high grade tumor areas. Although molecular approaches are providing
important information on renal intratumor heterogeneity, a focus on this topic from the practicing pathologist’
perspective is still pending.
Methods: Four distant tumor areas of 40 organ-confined clear cell renal cell carcinomas were selected for
histopathological and immunohistochemical evaluation. Tumor size, cell type (clear/granular), Fuhrman’s grade,
Staging, as well as immunostaining with Snail, ZEB1, Twist, Vimentin, E-cadherin, β-catenin, PTEN, p-Akt, p110α,
and SETD2, were analyzed for intratumor heterogeneity using a classification and regression tree algorithm.
Results: Cell type and Fuhrman’s grade were heterogeneous in 12.5 and 60 % of the tumors, respectively. If cell type
was homogeneous (clear cell) then the tumors were low-grade in 88.57 % of cases. Immunostaining heterogeneity
was significant in the series and oscillated between 15 % for p110α and 80 % for Snail. When Snail immunostaining
was homogeneous the tumor was histologically homogeneous in 100 % of cases. If Snail was heterogeneous, the
tumor was heterogeneous in 75 % of the cases. Average tumor diameter was 4.3 cm. Tumors larger than 3.7 cm were
heterogeneous for Vimentin immunostaining in 72.5 % of cases. Tumors displaying negative immunostaining for both
ZEB1 and Twist were low grade in 100 % of the cases.
Conclusions: Intratumor heterogeneity is a common event in clear cell renal cell carcinoma, which can be monitored
by immunohistochemistry in routine practice. Snail seems to be particularly useful in the identification of intratumor
heterogeneity. The suitability of current sampling protocols in renal cancer is discussed.
Keywords: Clear cell renal cell carcinoma, Intratumor heterogeneity, Epithelial to mesenchymal transition,
Immunohistochemistry, Snail, Tumor samplingBackground
Renal cancer is among the most common malignancies
in men and women in Western countries, with more
than 61000 estimated new cases in the United States in
2015 [1]. Clear cell renal cell carcinoma (CCRCC) is
the most frequent renal cancer histologic subtype, ac-
counting for about 70 % of renal carcinomas [2].
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able clinical course and usually displays resistance to
radio- and chemotherapy, surgery being the only effect-
ive treatment to date.
CCRCC is a paradigm of an intrinsically heteroge-
neous neoplasm and most problems with its clinical
management rely on this point. Intratumor heterogen-
eity (ITH) in CCRCC follows a spatial and temporal
branched pattern [3–5], with multiple cell clones evolv-
ing independently from each other during tumor evolu-
tion. This fact reflects the complexity of tumor biology
[6] and adds further difficulties to define effective tar-
geted treatments against this neoplasm [7]. CCRCC ITH
has been specifically studied in the last years from article is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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few studies addressing the problem from a clinical rou-
tine approach [10–12].
The aim of this study was to evaluate the ITH of
the expression of several epithelial to mesenchymal
transition (EMT) markers and PI3K/PTEN/Akt-path-
way markers, as assessed by immunohistochemistry,
and its relationship with standard histopathological
prognosis parameters in a series of 40 CCRCC col-
lected prospectively.
Methods
The authors declare that all the experiments carried out
in this study comply with current Spanish and European
Union legal regulations, and have been approved by the
Ethical and Scientific Committees of the Basque Country
Public Health System (Osakidetza) (CEIC-E 2015/060).
Forty organ-confined CCRCCs from two Spanish med-
ical institutions were included prospectively in the study
from September 2011 to June 2012. Cases showing gross
hemorrhage, necrosis or hard whitish areas indicative of
sarcomatoid transformation were excluded. All the cases
were collected prospectively, diagnosed and classified
by the same pathologist in each hospital following
similar criteria. Clinical data were retrieved from med-
ical histories.
On gross examination, four distant zones were sampled
in each tumor and then formalin-fixed and paraffin-
embedded following routine methods. Whenever possible,
samples were obtained in the cardinal points of the largest
tumor slice and had to be similar to the naked eye. Oncea b
c d
Fig. 1 Intratumor heterogeneity in adjacent tumor areas of clear cell rena
granular cells, b Papillary and solid cell tumor architecture, c High (papilla
grades in clear cells (solid pattern)the resulting hematoxylin-eosin (HE) slides were histologi-
cally reviewed, a 2.5 mm-in-diameter tumor sample was
selected in each block to build tissue microarrays (TMA).
TMA were performed with the resulting 160 tumor sam-
ples (4 areas each case, 40 cases). Samples were placed
randomly in the TMA to assure blind evaluation. Each
TMA contained an internal control.
Standard histopathologic data were evaluated on HE
stained slides (Fig. 1), including cell-type (clear vs.
granular), Fuhrman’s grade [classical (G1, G2, G3 and
G4) and grouped in low (G1/2) and high (G3/4) grades],
tumor diameter, and pT UICC staging (pT1a, pT1b and
pT2). Tumors were considered histologically heteroge-
neous when at least one of the four samples of each
tumor in the TMA had different cell type and/or grade.
Immunohistochemical staining was performed in au-
tomated immunostainers (EnVision FLEX, Dako Auto-
stainer Plus, Dako, Glostrup, Denmark; and BenchMark
Ultra, Ventana Medical Systems, Tucson, AZ, USA)
following routine methods. Tris-EDTA was used for
antigen retrieval in all cases. Negative controls were
slides not exposed to the primary antibody, and these
were incubated in PBS and then processed under the
same conditions as the test slides. The analysis was per-
formed using a Nikon Eclipse 80i microscope (Tokyo,
Japan). A panel of antibodies against EMT markers (Snail,
Twist, ZEB1, β-catenin, E-cadherin, and Vimentin), PI3K/
PTEN/Akt pathway-related markers (PTEN, p110α, p-
Akt), as well as SETD2, was tested (Fig. 2). Table 1 shows
the source and working dilutions of these antibodies.
Heterogeneous immunostaining category was assignedl cell carcinomas on routine hematoxylin-eosin slides. a Clear and





Fig. 2 Immunohistochemical pattern in clear cell renal cell carcinomas displaying nuclear and/or cytoplasmic and/or membranous staining. a Snail,
b Twist, c ZEB1, d β-catenin, e E-cadherin, f Vimentin, g PTEN, h p110α, i p-Akt, j SETD2
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tected among the four samples of each tumor. Cases were
considered homogeneous when the four samples of each
tumor displayed the same immunohistochemical profile,
and could be positive or negative.Table 1 List of antibodies tested in the study
Ab Source/code Dilution
Snail Abcam, ab180714 polyclonal ↑ pH 1:75
Twist Santa Cruz, sc15393 polyclonal ↓ pH 1:250
ZEB1 Santa Cruz, sc25388 polyclonal ↑ pH 1:100
β-catenin Cell Marque, 760-4242 monoclonal ↑ pH prediluted
E-cadherin Roche, Ventana, 790-4497 monoclonal ↑ pH prediluted
Vimentin Roche, Ventana, 790-2917 monoclonal ↑ pH prediluted
PTEN (6H2) Dako, M3627 monoclonal ↑ pH 1:50
p110α Pierce, PA5-27192 polyclonal ↓ pH 1:500
Akt Life Technologies, 700392 monoclonal ↑ pH 1:500
SETD2 Pierce, PA5-34934 polyclonal ↑ pH 1:500In a preliminary analysis, an independent 2-group t
test was performed to check if age, sex or tumor size
were different in the two conditions, heterogeneous vs.
homogeneous (t test function in R, r-project.org). After-
wards, we performed classification and attribute selec-
tion methods for ITH. First, we chose ITH as the
response variable to perform classification, coding it in a
binary variable with two values, to be heterogeneous or
not. Next, a classification and regression tree (CART)
algorithm was performed using a 10-fold stratified cross-
validation for testing. In particular, the CART algorithm
was applied using the Waikato Environment for Know-
ledge Analysis (WEKA) [13]. Clinical, histological and
immunohistochemical descriptors were selected to ob-
tain the classification rules for the heterogeneity re-
sponse; in particular, we used age, sex, simple Fuhrman’s
grade (grades from 1 to 4), grouped Fuhrman’s grade
[low grade (G1/2) and high grade (G3/4)], tumor diam-
eter, pT staging, cell type (clear vs. granular) and immu-
nostaining results of all the antibodies tested.
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relevant descriptors (those really affecting the classifica-
tion performance) from the irrelevant ones (those which
did not contribute to the classification performance).
Attribute selection was performed using three different
algorithms (a best-first search, a rank-search, and a
random-search) and the results did not differ between
the three methods.
Results
There was a male predominance in the series (30 M/
10 F) with an average age of 62.3 years (range, 33–88).
Tumor diameter oscillated between 1 and 10 cm (aver-
age, 4.3 cm). Following the aforementioned method-
ology, all the cases were organ confined and pT
distribution was as follows: pT1a, 21 cases (52.5 %);
pT1b, 17 cases (42.5 %); pT2: 2 cases (5 %). On HE
stained sections 35 cases (87.5 %) were homogeneous
and 5 heterogeneous (12.5 %) with respect to cell type.
All the homogeneous cases were composed of conven-
tional clear cells. Heterogeneous cases combined clear
and granular cells. No case composed exclusively by
granular cells was identified. Fuhrman’s grade [14] was
homogeneous in the four samples in 16 cases (40 %), 11
of them being G1 and 5 G2, and heterogeneous in 24
cases (60 %). Grouped grading distribution displayed 32
homogeneous (80 %) and 8 heterogeneous (20 %) cases.
All homogeneous cases in the series were low grade
(G1/2) tumors (100 %).
Immunohistochemical results for ITH are summarized
in Table 2. Briefly, Snail immunostaining was heteroge-
neous in 80 % of cases (32/40), Twist in 40 % (16/40),
ZEB-1 in 62.5 % (25/40), β-catenin in 37.5 % (15/40), E-
cadherin in 37.5 % (15/40), Vimentin in 50 % (20/40),
PTEN in 35 % (14/40), p110α in 15 % (6/40), p-Akt in
30 % (12/40), and SETD2 in 42.5 % (17/40). Immuno-
staining pattern did not show any difference between G3
and G4 areas. Snail immunostaining showed a relationTable 2 Immunohistochemical results
Homogeneous Heterogeneous
Abs Positive Negative
Snail 8 0 32 (80 %)
Twist 1 23 16 (40 %)
ZEB-1 1 14 25 (62.5 %)
β-catenin 22 3 15 (37.5 %)
E-cadherin 0 25 15 (37.5 %)
Vimentin 18 2 20 (50 %)
PTEN (6H2) 0 26 14 (35 %)
p110α 34 0 6 (15 %)
Akt 0 28 12 (30 %)
SETD2 23 0 17 (42.5 %)with Fuhrman’s grade: all high grade (G3/4) CCRCC
were Snail heterogeneous and all Snail homogeneous
CCRCC were low grade tumors (G1/2). Also, ZEB1 and
Twist immunostainings were correlated with grade: if
both ZEB1 and Twist immunostaining was negative,
then tumor grade was low in 100 % of the cases.
We obtained three different classification results from
applying the CART algorithm to different response vari-
ables (Table 3). Although in general the output of a
CART algorithm might be a decision tree with multiple
branches, for the particular situation of our data sets,
trees only had 2 branches, resulting in only one deter-
minant variable for the three particular situations. First,
considering all possible descriptors and ITH as the
response variable, the decision tree of the CART classi-
fication showed that the only classifier variable was
Snail immunostaining. Thus, if Snail immunostaining
was homogeneous, the tumor was histologically homo-
geneous in all cases. By contrast, if Snail immunostain-
ing was heterogeneous, the tumor was histologically
heterogeneous in 75 % of cases. Using this classification
scheme, 80 % of the cases in the series were correctly
classified. Any other variable, alone or in combination,
was not relevant for ITH.
A second CART classification was performed consider-
ing Grade as the response variable. In this case, cell type
(clear vs. granular) variable was the best one to classify
the response. If cell type was ‘clear’ (group 1 in
Table 3), then Grade was classified as G1-G2 with
88.57 % of correct classified instances. If cell type was
a mixture of ‘clear and granular’ (group 2 in Table 3),
then the Grade was G3-G4 with 80 % of correctness.
Using this classification scheme, 87.5 % of the cases in
the series were correctly classified. Any other variable,
alone or in combination, was not relevant for hetero-
geneity in Grade classification.
Finally, a third CART classification analysis was per-
formed choosing tumor diameter, Grade, grouped Grade
and cell type, and combinations of them, as descriptors,
and the rest of variables as response variables. This ana-
lysis showed that Vimentin was the only variable classi-
fied with correctness higher than 66 %. The rest of
variables gave a poorer performance. This analysis un-
veiled that those samples with a tumor diameter larger
than 3.7 cm were heterogeneous for Vimentin immuno-
staining with an accuracy of 72.5 %.
Discussion
ITH is an inherent phenomenon in carcinogenesis
that is being intensively analyzed using massive se-
quencing tools in many human neoplasms, kidney in-
cluded [3–5, 7–9, 15]. However, pathological studies
related with ITH under daily routine conditions are
scarce. At this respect, Nassar et al. [16] documented
Table 3 CART classification results over three different response variables (first column) revealed three different determinant
variables (second column)
Response variable Determinant variable Individual Correctness Individual Correctness Total
Correctness1 2
Grade Heterogeneity Snail immunostaining Snail het - > Grade het Snail hom - > Grade hom 80 %
75 % (24/32) 100 % (8/8) (32/40)
Grade Cell type Clear cell (hom) - > Grade
low (G1/G2)
Granular cell (het) - > Grade
high (G3/G4)
87.5 %
88.57 % (31/35) 80 % (4/5) (35/40)
Diameter Vimentin Diam > 3.7 - > Vim het Diam < =3.7 - > Vim hom 72.5 %
72.72 % (16/22) 72.22 % (13/18) (29/40)
Individual Correctness (columns 3 and 4) shows the classification performance with respect to each group of the response variable and Total Correctness (column 5)
shows the overall classification performance applied to the entire dataset
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highlighted the negative clinical impact of potential
false negative immunohistochemical results obtained
after a study performed in small, probably non repre-
sentative, core biopsies. In renal cancer this is an im-
portant issue since renal tumors are frequently big in
size, and current protocols of tumor sampling recom-
mend the selection for microscopic study of one block
per centimeter of tumor plus an additional sample of
every suspicious area on naked eye [17–19]. Following
these guidelines, more than 90 % of the neoplastic tis-
sue in many renal tumors may escape the pathologist’s
routine analysis. This fact makes difficult to quantify
the nature and extent of ITH, if present, in most
CCRCC. Although pathologists recognize by naked eye
whitish hard areas related to sarcomatoid transform-
ation, as well as hemorrhagic and/or necrotic foci, there
is a significant amount of ITH hidden in apparently
homogeneous areas, as recently reported [10–12]. Fur-
thermore, an incomplete tumor sampling may justify
the unexpected aggressive behavior that some low-
grade CCRCC show [12]. The present work has shown
the relationship between cell type and Grade in
CCRCC, since a mixture of conventional clear and
granular cells determines high tumor Grade (G3/G4) in
more than 83 % of cases.
Two recent studies on CCRCC have contributed to
know more about ITH from a practical perspective. The
first one intended to identify how much information is
lost in routine practice after following the official sam-
pling protocols. For such a purpose, a total tumor sam-
pling, an unsuitable strategy in daily routine, was
performed in 47 prospective CCRCC, and the histo-
logical analysis revealed a significant higher number of
high grade tumors than with conventional sampling
[10]. This finding raises serious doubts about the ap-
propriateness of currently accepted CCRCC sampling
protocols, suggesting that in some histopathological
examinations data potentially crucial for the patientmight be ignored. The second study used data mining
tools and showed that only CCRCC tumors with less
than 3.8 cm in diameter are always histologically
homogeneous [12]. In addition, the present report
shows that CCRCC tumors with more than 3.7 cm dis-
play ITH for Vimentin immunostaining. Interestingly,
both size numbers are very close to the pathological
staging frontier between pT1a and pT1b, suggesting
that 4 cm in diameter is the size in which ITH ap-
pears visible on both histological and immunohisto-
chemical settings. This finding, however, does not
infer that ITH at gene mutation status level follows
the same tendency.
The present work was also designed to investigate the
utility of immunohistochemistry in the identification of
ITH in CCRCC. The panel of protein markers used was
selected considering their potential roles in the develop-
ment of tumor aggressiveness, tumor diversification and
metastatic processes.
EMT is a cellular mechanism extensively reviewed in
the literature [3, 9, 20, 21]. The process explains how,
under certain conditions, epithelial cells transform into
mesenchymal cells. Briefly, EMT includes first the loss
of the apical-basal polarity and cell-to-cell lateral junc-
tions and then the acquisition of spindle cell shape, end-
to-end polarity, and migration abilities. This change
occurs in three different settings: embryonic develop-
ment, tissue repair and neoplasia. The EMT concept is
indispensable to understand the invasive properties and
the metastatic capacities of carcinomas [22–27]. Inter-
estingly, EMT may be a reversible process, what is called
mesenchymal-to-epithelial transition (MET), which par-
tially explains why high grade carcinomas may appear in
distant metastases with an extremely low grade pheno-
type [22, 23, 28].
The immunohistochemical expression of several EMT
markers in renal cell carcinomas has been previously
reported. For instance, Clusterin and Twist expression
has been related with tumor aggressiveness [29], tumor
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has focused on the immunohistochemical distribution
of seven EMT markers [including cell-surface (E-cad-
herin) markers, cytoskeletal and cytoskeletal-associated
(vimentin, β-catenin) proteins, and transcription factors
(Snail, ZEB1, Twist, β-catenin)] in the context of ITH
in CCRCC.
The Snail antibody tested in this study recognizes both
Snail1 and Snail2. Snail1 is a zinc-finger transcription
factor directly involved in the repression of E-cadherin
transcription thus promoting the acquisition of a mesen-
chymal phenotype [28, 32]. Snail1 seems to be activated
by ghrelin, an appetite-regulating molecule that pro-
motes growth hormone release [33]. The immunohisto-
chemical expression of Snail1 in CCRCC has been
associated to advanced stage, high grade, local invasion
and metastases [34]. A recent study has confirmed that
Snail1 immunostaining predicts early recurrence and
poor survival in CCRCC patients [35]. In our series, all
high grade CCRCC tumors, including 3 G4 cases,
displayed positive immunostaining for Snail. By contrast,
Snail negative CCRCC were always low-grade. In
addition, we have found that Snail positive immuno-
staining determines ITH, as defined by pathological
analysis. The effect of Snail1 in promoting EMT can be
suppressed by Klotho, as demonstrated by Zhu et al. in
a recent study [36]. Klotho, an anti-aging and tumor
suppressor protein expressed in renal tubular cells, in-
hibits PI3K/Akt/GSK3β/Snail signaling thus suppress-
ing EMT, tumor invasion and migration. How the
Snail1-associated transcriptional cell profile may be re-
lated with ITH in CCRCC remains to be investigated.
Twist is a transcription factor classically involved in
embryonic development [37]. In addition, Twist plays a
role in tumor growth, cell invasion and metastases by
regulating neoangiogenesis and extracellular matrix
degradation [29]. Twist expression is associated with bad
prognosis in CCRCC [29, 30]. We have found heteroge-
neous Twist immunostaining in 16 CCRCC (40 %) and
homogeneously positive staining in 1 case, although
Twist was an irrelevant variable for classification of ITH
and grade.
ZEB1 and ZEB2 are zinc-finger E-box binding tran-
scription factors crucial for the activation of EMT [21].
ZEB1 gene is up-regulated in primary renal tumors com-
pared with their metastases, suggesting a reversal MET
process in the metastatic seed [38]. The miRNA-200
family is directly involved in EMT and MET processes
targeting the E-cadherin repressors ZEB1 and ZEB2
[28, 39]. Interestingly, CCRCC show down-regulation
of all the members of this miRNA family [40], a fact
that may be useful in the differential diagnosis of
CCRCC [41, 42]. In our study, ZEB1 immunostaining was
heterogeneous in 25 cases (62.5 %) and homogeneouslypositive in 1 case, but after attribute selection methods,
ZEB1 immunostaining was a non-relevant variable for ITH
classification as well as for tumor grade classification. How-
ever, a combined negative immunostaining for ZEB1 and
Twist was always associated to low grade (G1/2) tumors,
suggesting that the combined analysis of these two markers
could be informative for CCRCC prognosis.
β-catenin is a cytoplasmic protein that links cadher-
ins to cytoskeleton. Additionally, it serves as a co-
transcriptional activator in the nucleus [43]. β-catenin
is expressed in neoplastic cells undergoing EMT, espe-
cially at the stromal invasion front, as reported in
colorectal adenocarcinoma [44]. β-catenin dysregula-
tion has been associated to aggressive clinical course
and shorter survival in CCRCC [45]. A heterogeneous
immunohistochemical expression of this protein has
been demonstrated in 15 cases in the present series,
but this number has not reached any significance in
the CART algorithms. In addition, β-catenin immu-
nostaining was diffusely positive (nucleus and cyto-
plasmic membrane) in 22 cases and totally negative
in 3 cases.
E-cadherin is expressed at the surface of epithelial cells
in normal conditions, decreasing in abundance during
EMT process in a switch with N-cadherin [46]. E-
cadherin immunostaining is completely lost in 60 % of
our cases. By contrast, focal and diffuse immunostaining
was detected in 15 and 1 cases, respectively. After attri-
bute selection methods, E-cadherin immunostaining was
not a relevant variable for ITH.
Vimentin is an intermediate filament that has been im-
plicated in all EMT scenarios (embryonal development,
tissue repair and cancer progression) [28]. Low mRNA
levels of Vimentin correlate with a better outcome of
CCRCC patients [38]. From a practical viewpoint,
Vimentin is usually co-expressed with cytokeratins
and CD10, helping in the routine differential diagnosis
of renal tumors [47]. The pathologist’s experience re-
veals that Vimentin immunostaining is sometimes
patchy in CCRCC. In our study, Vimentin immuno-
staining was heterogeneous in half of the cases (20
cases), being homogeneously positive in 18 cases and
totally negative in 2 cases. As previously mentioned,
our classification analysis reveals a relation between
tumor size larger than 3.7 cm and heterogeneous
Vimentin immunostaining.
p110α, PTEN and p-Akt are major signaling compo-
nents in the pathway leading to mTOR activation, and
were included in our study because of their importance
in the molecular profiling of CCRCC and their emerging
utility as prognostic markers and therapeutic targets
[48–51]. p110α is a major catalytic subunit of the PI3K
enzyme and displays pro-oncogenic properties by virtue
of generation of the phospho-inositide PIP3, which
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effector kinase. Phospho-Akt (p-Akt) executes pro-
oncogenic functions by phosphorylation of multiple pro-
tein substrates, being an important upstream activator of
mTOR. This effect is counteracted by the action of the
PTEN PIP3 phosphatase [52–54]. Most of the tumor
samples analyzed in our study displayed p110α positive
and PTEN negative immunostaining, in agreement with
their respective oncogenic and tumor suppressive func-
tions in renal cancer [55]. However, we did not find cor-
relation between PTEN and p-Akt (as a measurement of
Akt activation) immunostaining in most of the tumors,
suggesting the existence of PTEN-independent mecha-
nisms driving Akt phosphorylation and activation in
CCRCC, as previously proposed by others [56]. Most
cases (33/40) displayed homogenous positive staining for
p110α, whereas the majority of samples were homoge-
nously negative for PTEN (26/40) or p-Akt (28/40).
Classification analysis with these markers was not rele-
vant for ITH.
SETD2 is the main methyltransferase responsible for
trimethylation of histone-3 at lysine-36 and is encoded
in chromosome 3, whose LOH has been reported to be
an early event in CCRCC [4]. In spite of the fact that this
gene is mutated in 4–8 % of CCRCC [3], there is no
evidence that these mutations carry clinical significance
[57]. Very recent studies have shown that SETD2 loss of
function causes dysfunctional DNA replication and re-
pair, which promotes subclonal diversification. This con-
tributes to ITH acting at early branches of the tumor
phylogenetic tree [5]. We have detected a heterogeneous
immunostaining of SETD2 protein in almost half of the
cases (42.5 %), but SETD2 was an irrelevant variable for
classification of IHT and grade.Conclusions
ITH is a common event in CCRCC, even in organ-
confined tumors. Aside from the molecular approaches,
conventional histologic and immunohistochemical stud-
ies may also demonstrate ITH in CCRCC, as revealed in
this study. For such a purpose, Snail immunostaining
appears to be an important marker. The high incidence
of ITH in CCRCC recommends a wide sampling of the
surgical specimens to guarantee that crucial data for the
patient are not overlooked.
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